Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 45 of 139 for:    johnstown

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT02164513
First received: June 12, 2014
Last updated: September 22, 2016
Last verified: September 2016
  Purpose
The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. Published studies which assessed the use of an 'open' triple therapy (use of Inhaled Corticosteroid [ICS]/ Long-acting Muscarinic Receptor Antagonists [LAMA])/ Long Acting Beta-Agonist [LABA] delivered via multiple inhalers) in moderate-severe COPD patients, reported improvements in lung function, Health Related Quality of Life (HRQoL), hospitalization rates and rescue medication use, compared to dual therapy (ICS/LABA) or LAMA alone. These studies have also shown similar safety profile with dual or monotherapy doses for periods of up to one year. Given the clinical experience with FF, UMEC and VI, and that the associated risks with these compounds are anticipated from their known pharmacology, the potential benefit of a new therapy option in patients with moderate to severe COPD supports the further development of the closed triple combination (delivered via one inhaler). In the current study subjects meeting all inclusion/exclusion criteria will complete 2-week run-in period; 52 week treatment period and a 1-week safety follow-up period. Eligible subjects will be randomized to one of the following double-blind treatment groups FF/UMEC/VI 100 micrograms (mcg)/62.5 mcg/25 mcg once daily (QD), FF/VI 100 mcg/25 mcg QD, or UMEC/VI 62.5 mcg/25 mcg QD

Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: fluticasone furoate (FF)
Drug: vilanterol (VI)
Drug: umeclidinium bromide (UMEC)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Annual rate of on-treatment moderate and severe exacerbations comparing FF/UMEC/VI with UMEC/VI [ Time Frame: Up to Week 52 ] [ Designated as safety issue: No ]
    Annual rate of on-treatment moderate and severe exacerbations will be compared between FF/UMEC/VI with UMEC/VI. Moderate exacerbation is defined as worsening symptoms of COPD that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbation will be defined as worsening symptoms of COPD that require treatment with in-patient hospitalization

  • Annual rate of on-treatment moderate and severe exacerbations comparing FF/UMEC/VI with FF/VI [ Time Frame: Up to Week 52 ] [ Designated as safety issue: No ]
    Annual rate of on-treatment moderate and severe exacerbations will be compared between FF/UMEC/VI with FF/VI. Moderate exacerbation is defined as worsening symptoms of COPD that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbation will be defined as worsening symptoms of COPD that require treatment with in-patient hospitalization


Secondary Outcome Measures:
  • Change from baseline trough FEV1 at Week 52 comparing FF/UMEC/VI with FF/VI [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: No ]
    Forced Expiratory Volume (FEV1) is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment at Week 52 is defined as the FEV1 values obtained prior to morning dose of investigational product. Change from baseline is the Week 52 value for trough FEV1 minus baseline value (Visit 1),will be compared between FF/UMEC/VI with FF/VI

  • Change from baseline St George's Respiratory Questionnaire (SGRQ) total score at Week 52 comparing FF/UMEC/VI with FF/VI [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: No ]
    The SGRQ is a disease-specific questionnaire designed to measure the impact of respiratory disease and its treatment on a COPD patient's health related quality of life (HRQoL) overall summary score, scores for the individual domains of symptoms, activity and impact Change from baseline is the Week 52 value for SGRQ minus baseline value (Visit 1), will be compared between FF/UMEC/VI with FF/VI

  • Time to first on-treatment moderate or severe exacerbation comparing FF/UMEC/VI with FF/VI and with UMEC/VI [ Time Frame: Day 1 to Week 52 ] [ Designated as safety issue: No ]
    Time to first on-treatment moderate or severe exacerbation of COPD will be compared for FF/UMEC/VI with FF/VI and with UMEC/VI. Moderate exacerbation is defined as worsening symptoms of COPD that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbation will be defined as worsening symptoms of COPD that require treatment with in patient hospitalization

  • Annual rate of on-treatment moderate and severe exacerbations comparing FF/UMEC/VI with UMEC/VI in the subset of subjects with a blood eosinophil count >=150cells/ MicroLitre (mcl) [ Time Frame: Up to Week 52 ] [ Designated as safety issue: No ]
    The annual rate of moderate and severe COPD exacerbation will be compared for FF/UMEC/VI with UMEC/VI during treatment in subjects specific to the subgroup with raised eosinophil count>=150 cells/ mcl

  • Time to first on-treatment moderate or severe exacerbation comparing FF/UMEC/VI with UMEC/VI in the subset of subjects with a blood eosinophil count>=150cells/mcl [ Time Frame: Day 1 to Week 52 ] [ Designated as safety issue: No ]
    Time-to-first moderate or severe exacerbation of COPD event will be compared for FF/UMEC/VI with UMEC/VI in subjects specific to the subgroup with raised eosinophil count >=150 cells/mcl

  • Annual rate of on-treatment severe exacerbations comparing FF/UMEC/VI with FF/VI and with UMEC/VI [ Time Frame: Up to Week 52 ] [ Designated as safety issue: No ]
    Annual rate of on-treatment severe exacerbation will be defined as worsening symptoms of COPD that require treatment with in patient hospitalization will be compared for FF/UMEC/VI with FF/VI and with UMEC/VI


Estimated Enrollment: 10000
Study Start Date: June 2014
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: fluticasone furoate/umeclidinium bromide/vilanterol
Eligible Subjects completing 2-weeks run-in period will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg QD (morning) for a period of 52 weeks via DPI
Drug: fluticasone furoate (FF)
FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg
Drug: vilanterol (VI)
VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
Drug: umeclidinium bromide (UMEC)
UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg
Experimental: fluticasone furoate/vilanterol
Eligible Subjects completing 2-weeks run-in period will receive FF/VI 100 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI)
Drug: fluticasone furoate (FF)
FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg
Drug: vilanterol (VI)
VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
Experimental: umeclidinium bromide/vilanterol
Eligible Subjects completing 2-weeks run-in period will receive UMEC/VI 62.5 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI
Drug: vilanterol (VI)
VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
Drug: umeclidinium bromide (UMEC)
UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg

  Eligibility

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Informed Consent: A signed and dated written informed consent prior to study participation
  • Type of subject: Outpatient
  • Age: Subjects 40 years of age or older at Visit 1
  • Gender: Male or female subjects. A female is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age appropriate, > 45 years, in the absence of hormone replacement therapy OR Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly (i.e. in accordance with the approved product label and the instructions of the physician for the duration of the study - screening to safety follow-up contact): Abstinence; Oral Contraceptive, either combined or progestogen alone; Injectable progestogen; Implants of levonorgestrel; Estrogenic vaginal ring; Percutaneous contraceptive patches; Intrauterine device (IUD) or intrauterine system (IUS); Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, "documented" refers to the outcome of the investigator's/designee's medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records. Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)
  • COPD Diagnosis: An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society
  • Smoking History: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years at screening (visit 1) [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Note: Pipe and/or cigar use cannot be used to calculate pack-year history
  • Severity of COPD symptoms: A score of >=10 on the COPD Assessment Test (CAT) at screening
  • Severity of COPD Disease: A post-albuterol/salbutamol FEV1/ Forced Vital Capacity (FVC) ratio of <0.70 at Screening
  • Existing COPD maintenance treatment: Subject must be receiving daily maintenance treatment for their COPD for at least 3 months prior to Screening. Note: Subjects receiving only Pro re nata (PRN) COPD medications are not eligible
  • History of Exacerbations: Subjects must demonstrate: a post-bronchodilator FEV1 <50% predicted normal and a documented history of >= 1 moderate or severe COPD exacerbation in the previous 12 months OR a post-bronchodilator 50% <=FEV1 < 80% predicted normal and a documented history of >= 2 moderate exacerbations or a documented history of >=1 severe COPD exacerbation (hospitalized) in the previous 12 months. Note: Percent predicted will be calculated using the European Respiratory Society Global Lung Function Initiative reference equations. Note: A documented history of a COPD exacerbation (e.g., medical record verification) is a medical record of worsening COPD symptoms that required systemic/oral corticosteroids and/or antibiotics (for a moderate exacerbation) or hospitalization (for a severe exacerbation). Prior use of antibiotics alone does not qualify as an exacerbation history unless the use was associated with treatment of worsening symptoms of COPD, such as increased dyspnea, sputum volume, or sputum purulence (color). Subject verbal reports are not acceptable
  • Liver function tests: alanine aminotransferase (ALT) <2x upper limit of normal (ULN); alkaline phosphatase <=1.5xULN; bilirubin <=1.5xULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
  • French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category

Exclusion Criteria:

  • Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study
  • Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD)
  • Alpha1-antitrypsin deficiency: Subjects with Alpha1-antitrypsin deficiency as the underlying cause of COPD
  • Other respiratory disorders: Subjects with active tuberculosis, lung cancer, significant bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
  • Lung resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening
  • Risk Factors for Pneumonia: immune suppression (e.g. human immunodeficiency virus [HIV], Lupus) or other risk factors for pneumonia (e.g. neurological disorders affecting control of the upper airway, such as Parkinson's Disease, Myasthenia Gravis). Patients at potentially high risk (e.g. very low BMI, severely malnourished, or very low FEV1) will only be included at the discretion of the Investigator
  • Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least 14 days prior to Screening and at least 30 days following the last dose of oral/systemic corticosteroids (if applicable). In addition, any subject that experiences pneumonia and/or moderate or severe COPD exacerbation during the run-in period will be excluded
  • Other Respiratory tract infections that have not resolved at least 7 days prior to screening
  • Abnormal Chest x-ray(CXR): Chest x-ray (posteroanterior and lateral) reveals evidence of pneumonia or a clinically significant abnormality not believed to be due to the presence of COPD, or another condition that would hinder the ability to detect an infiltrate on CXR (e.g. significant cardiomegaly, pleural effusion or scarring). All subjects will have a chest x-ray at Screening Visit 1 (or historical radiograph or computerised tomography (CT) scan obtained within 3 months prior to screening) that will be over-read by a central vendor. Note: Subjects who have experienced pneumonia and/or moderate or severe COPD exacerbation within 3 months of screening must provide a post pneumonia/exacerbation chest x-ray to be over-read by the central vendor or have a chest x-ray conducted at screening. For sites in Germany: If a chest x-ray (or CT scan) within 3 months prior to Screening (Visit 1) is not available, approval to conduct a diagnostic chest x-ray will need to be obtained from the Federal Office for Radiation Protection (Bundesamt für Strahlenschutz [BfS])
  • Other diseases/abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study
  • Unstable liver disease as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice, cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • Note: Chronic stable hepatitis B and C are acceptable if the subject otherwise meets entry criteria
  • Unstable or life threatening cardiac disease: subjects with any of the following at Screening (Visit 1) would be excluded: Myocardial infarction or unstable angina in the last 6 months; Unstable or life threatening cardiac arrhythmia requiring intervention in the last 3 months; New York Heart Association (NYHA) Class IV Heart failure
  • Abnormal and clinically significant 12-Lead Electrocardiogram (ECG) finding: Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility. The Principal Investigator will determine the clinical significance of each abnormal ECG finding in relation to the subject's medical history and exclude subjects who would be at undue risk by participating in the trial. An abnormal and clinically significant finding that would preclude a subject from entering the trial is defined as a 12-lead tracing that is interpreted as, but not limited to, any of the following: atrial fibrillation (AF) with rapid ventricular rate >120 beats per minute); sustained or nonsustained ventricular tachycardia (VT); Second degree heart block Mobitz type II and third degree heart block (unless pacemaker or defibrillator had been inserted); QT interval corrected for heart rate (QTcF) >=500 milliseconds (msec) in patients with QRS <120 msec and QTcF >=530 msec in patients with QRS >=120 msec
  • Contraindications: A history of allergy or hypersensitivity to any corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the Investigator contraindicates study participation
  • Cancer: Subjects with carcinoma that has not been in complete remission for at least 5 years. Subjects who have had carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded based on the 5 year waiting period if the subject has been considered cured by treatment
  • Oxygen therapy: Use of long-term oxygen therapy (LTOT) described as resting oxygen therapy >3 Liter/minute (L/min) (Oxygen use =<3L/min flow is not exclusionary)
  • Medication prior to spirometry: Subjects who are medically unable to withhold their albuterol/salbutamol for the 4-hour period required prior to spirometry testing at each study visit
  • Pulmonary rehabilitation: Subjects who have participated in the acute phase of a Pulmonary Rehabilitation Program within 4 weeks prior to Screening or subjects who plan to enter the acute phase of a Pulmonary Rehabilitation Program during the study. Subjects who are in the maintenance phase of a Pulmonary Rehabilitation Program are not excluded
  • Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years
  • Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits
  • Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study
  • Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or study site, or immediate family members of the aforementioned that is involved with this study
  • Inability to read: In the opinion of the Investigator, any subject who is unable to read and/or would not be able to complete study related materials
  • Medication prior to screening: Use of the following medications within the following time intervals prior to Screening (Visit 1) or during the study: Long term antibiotic therapy Subjects receiving antibiotics for long term therapy are not eligible for the study (Antibiotics are allowed for the short term treatment of an exacerbation or for short term treatment of other acute infections during the study); Systemic, Oral, parenteral corticosteroids 30 days (Except during the study oral/systemic corticosteroids may be used to treat COPD exacerbations/pneumonia) Intra-articular injections are allowed; Any other investigational drug (30 days or 5 half lives whichever is longer)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02164513

  Hide Study Locations
Locations
United States, Alabama
GSK Investigational Site
Athens, Alabama, United States, 35611
GSK Investigational Site
Birmingham, Alabama, United States, 35215
GSK Investigational Site
Birmingham, Alabama, United States, 35216
GSK Investigational Site
Birmingham, Alabama, United States, 35294
GSK Investigational Site
Florence, Alabama, United States, 35630
GSK Investigational Site
Jasper, Alabama, United States, 35501
GSK Investigational Site
Mobile, Alabama, United States, 36608
GSK Investigational Site
Muscle Shoals, Alabama, United States, 35662
GSK Investigational Site
Sheffield, Alabama, United States, 35660
United States, Arizona
GSK Investigational Site
Chandler, Arizona, United States, 85284
GSK Investigational Site
Flagstaff, Arizona, United States, 86001
GSK Investigational Site
Glendale, Arizona, United States, 85306
GSK Investigational Site
Peoria, Arizona, United States, 85381
GSK Investigational Site
Phoenix, Arizona, United States, 85018
GSK Investigational Site
Phoenix, Arizona, United States, 85032
GSK Investigational Site
Tucson, Arizona, United States, 85723
GSK Investigational Site
Tucson, Arizona, United States, 85724-5023
GSK Investigational Site
Tucson, Arizona, United States, 85745
United States, California
GSK Investigational Site
Arcadia, California, United States, 91007
GSK Investigational Site
Bakersfield, California, United States, 93301
GSK Investigational Site
Chula Vista, California, United States, 91910
GSK Investigational Site
Encinitas, California, United States, 92024
GSK Investigational Site
Escondido, California, United States, 92025
GSK Investigational Site
Huntington Beach, California, United States, 92647
GSK Investigational Site
Long Beach, California, United States, 90808
GSK Investigational Site
Long Beach, California, United States, 90822
GSK Investigational Site
Mission Hills, California, United States, 91345
GSK Investigational Site
Modesto, California, United States, 95350
GSK Investigational Site
Newport Beach, California, United States, 92663
GSK Investigational Site
Palo Alto, California, United States, 94304
GSK Investigational Site
Reseda, California, United States, 91335
GSK Investigational Site
Riverside, California, United States, 92506
GSK Investigational Site
Rolling Hills Estates, California, United States, 90274
GSK Investigational Site
Sacramento, California, United States, 95821
GSK Investigational Site
San Diego, California, United States, 92117
GSK Investigational Site
Santa Ana, California, United States, 92705
GSK Investigational Site
Santa Monica, California, United States, 90404
GSK Investigational Site
Torrance, California, United States, 90505
GSK Investigational Site
Tustin, California, United States, 92780
GSK Investigational Site
Upland, California, United States, 91786
GSK Investigational Site
Vista, California, United States, 92083
United States, Colorado
GSK Investigational Site
Boulder, Colorado, United States, 80301
GSK Investigational Site
Colorado Springs, Colorado, United States, 80907
GSK Investigational Site
Fort Collins, Colorado, United States, 80538
GSK Investigational Site
Golden, Colorado, United States, 80401
United States, Connecticut
GSK Investigational Site
Danbury, Connecticut, United States, 06810
GSK Investigational Site
Hartford, Connecticut, United States, 06105
GSK Investigational Site
New Haven, Connecticut, United States, 06520
GSK Investigational Site
Stamford, Connecticut, United States, 06902
GSK Investigational Site
Waterbury, Connecticut, United States, 06708
GSK Investigational Site
West Haven, Connecticut, United States, 06516
United States, Florida
GSK Investigational Site
Bay Pines, Florida, United States, 33744
GSK Investigational Site
Boynton Beach, Florida, United States, 33436
GSK Investigational Site
Brandon, Florida, United States, 33511
GSK Investigational Site
Celebration, Florida, United States, 34747
GSK Investigational Site
Clearwater, Florida, United States, 33759
GSK Investigational Site
Clearwater, Florida, United States, 33765-2616
GSK Investigational Site
Daytona Beach, Florida, United States, 32117
GSK Investigational Site
Deland, Florida, United States, 32720
GSK Investigational Site
Edgewater, Florida, United States, 32132
GSK Investigational Site
Fort Lauderdale, Florida, United States, 33306
GSK Investigational Site
Fort Myers, Florida, United States, 33908
GSK Investigational Site
Gainesville, Florida, United States, 32608
GSK Investigational Site
Hollywood, Florida, United States, 33024
GSK Investigational Site
Jacksonville, Florida, United States, 32204
GSK Investigational Site
Jacksonville, Florida, United States, 32205
GSK Investigational Site
Jacksonville, Florida, United States, 32207
GSK Investigational Site
Jacksonville, Florida, United States, 32209
GSK Investigational Site
Jacksonville, Florida, United States, 32216
GSK Investigational Site
Leesburg, Florida, United States, 34748
GSK Investigational Site
Maitland, Florida, United States, 32751
GSK Investigational Site
Miami, Florida, United States, 33015
GSK Investigational Site
Miami, Florida, United States, 33137
GSK Investigational Site
New Port Richey, Florida, United States, 34652
GSK Investigational Site
Orlando, Florida, United States, 32825
GSK Investigational Site
Oviedo, Florida, United States, 32765
GSK Investigational Site
Pembroke Pines, Florida, United States, 33027
GSK Investigational Site
Pensacola, Florida, United States, 32503
GSK Investigational Site
Ponte Verda, Florida, United States, 32081
GSK Investigational Site
Port Charlotte, Florida, United States, 33952
GSK Investigational Site
Port Charlotte, Florida, United States, 33980
GSK Investigational Site
Port Orange, Florida, United States, 32127
GSK Investigational Site
Sarasota, Florida, United States, 34239
GSK Investigational Site
St. Petersburg, Florida, United States, 33704
GSK Investigational Site
Tampa, Florida, United States, 33603
GSK Investigational Site
Wellington, Florida, United States, 33414
United States, Georgia
GSK Investigational Site
Adairsville, Georgia, United States, 30103
GSK Investigational Site
Athens, Georgia, United States, 30606
GSK Investigational Site
Austell, Georgia, United States, 30106
GSK Investigational Site
Columbus, Georgia, United States, 31904
GSK Investigational Site
Conyers, Georgia, United States, 30094
GSK Investigational Site
Decatur, Georgia, United States, 30033
GSK Investigational Site
Duluth, Georgia, United States, 30096
GSK Investigational Site
Gainesville, Georgia, United States, 30501
GSK Investigational Site
Marietta, Georgia, United States, 30060
GSK Investigational Site
Rincon, Georgia, United States, 31326
GSK Investigational Site
Woodstock, Georgia, United States, 30189
United States, Idaho
GSK Investigational Site
Coeur D'Alene, Idaho, United States, 83814
United States, Illinois
GSK Investigational Site
Chicago, Illinois, United States, 60611
GSK Investigational Site
Elk Grove Village, Illinois, United States, 60007
GSK Investigational Site
Gillespie, Illinois, United States, 62033
GSK Investigational Site
Hines, Illinois, United States, 60124
GSK Investigational Site
O'Fallon, Illinois, United States, 62269
GSK Investigational Site
Oak Park, Illinois, United States, 60302
GSK Investigational Site
Quincy, Illinois, United States, 62301
GSK Investigational Site
Winfield, Illinois, United States, 60190
United States, Indiana
GSK Investigational Site
Evansville, Indiana, United States, 47714
GSK Investigational Site
Franklin, Indiana, United States, 46131
GSK Investigational Site
Greenfield, Indiana, United States, 46140
GSK Investigational Site
Muncie, Indiana, United States, 47303
United States, Iowa
GSK Investigational Site
Council Bluffs, Iowa, United States, 51503
GSK Investigational Site
Iowa City, Iowa, United States, 52242
United States, Kansas
GSK Investigational Site
Olathe, Kansas, United States, 66061
GSK Investigational Site
Topeka, Kansas, United States, 66606
GSK Investigational Site
Wichita, Kansas, United States, 67218
United States, Kentucky
GSK Investigational Site
Fort Mitchell, Kentucky, United States, 41017
GSK Investigational Site
Louisville, Kentucky, United States, 40218
GSK Investigational Site
Paducah, Kentucky, United States, 42003
United States, Louisiana
GSK Investigational Site
Crowley, Louisiana, United States, 70526
GSK Investigational Site
Lafayette, Louisiana, United States, 70508
GSK Investigational Site
New Orleans, Louisiana, United States, 70112
GSK Investigational Site
New Orleans, Louisiana, United States, 70115
GSK Investigational Site
New Orleans, Louisiana, United States, 70119
GSK Investigational Site
Shreveport, Louisiana, United States, 71103
GSK Investigational Site
Sunset, Louisiana, United States, 70584
United States, Maine
GSK Investigational Site
Bangor, Maine, United States, 04401
United States, Maryland
GSK Investigational Site
Columbia, Maryland, United States, 21044
GSK Investigational Site
Hollywood, Maryland, United States, 20636
United States, Massachusetts
GSK Investigational Site
Fall River, Massachusetts, United States, 02720
GSK Investigational Site
North Dartmouth, Massachusetts, United States, 02747
GSK Investigational Site
Pittsfield, Massachusetts, United States, 01201
GSK Investigational Site
Worcester, Massachusetts, United States, 01608
United States, Michigan
GSK Investigational Site
Ann Arbor, Michigan, United States, 48106
GSK Investigational Site
Southfield, Michigan, United States, 48034
GSK Investigational Site
Troy, Michigan, United States, 48085
United States, Minnesota
GSK Investigational Site
Duluth, Minnesota, United States, 55805
GSK Investigational Site
Edina, Minnesota, United States, 55435
GSK Investigational Site
Fridley, Minnesota, United States, 55432
GSK Investigational Site
Minneapolis, Minnesota, United States, 55402
GSK Investigational Site
Minneapolis, Minnesota, United States, 55407
GSK Investigational Site
Rochester, Minnesota, United States, 55905
GSK Investigational Site
St. Paul, Minnesota, United States, 55130
GSK Investigational Site
Woodbury, Minnesota, United States, 55125
United States, Mississippi
GSK Investigational Site
Jackson, Mississippi, United States, 39202
United States, Missouri
GSK Investigational Site
Chesterfield, Missouri, United States, 63017
GSK Investigational Site
Kansas City, Missouri, United States, 64128
GSK Investigational Site
St. Charles, Missouri, United States, 63301
GSK Investigational Site
St. Louis, Missouri, United States, 63141
GSK Investigational Site
St.Louis, Missouri, United States, 63141
United States, Montana
GSK Investigational Site
Butte, Montana, United States, 59701
GSK Investigational Site
Missoula, Montana, United States, 59808
United States, Nebraska
GSK Investigational Site
Fremont, Nebraska, United States, 68025
GSK Investigational Site
Grand Island, Nebraska, United States, 68803
GSK Investigational Site
Lincoln, Nebraska, United States, 68506
GSK Investigational Site
Omaha, Nebraska, United States, 68131
GSK Investigational Site
Omaha, Nebraska, United States, 68134
United States, Nevada
GSK Investigational Site
Las Vegas, Nevada, United States, 89106
GSK Investigational Site
Reno, Nevada, United States, 89503
United States, New Jersey
GSK Investigational Site
Marlton, New Jersey, United States, 08053
GSK Investigational Site
Moorestown, New Jersey, United States, 08057
GSK Investigational Site
Neptune, New Jersey, United States, 07753
United States, New Mexico
GSK Investigational Site
Albuquerque, New Mexico, United States, 87108
United States, New York
GSK Investigational Site
Albany, New York, United States, 12208
GSK Investigational Site
Bronx,, New York, United States, 10457
GSK Investigational Site
Bronxville, New York, United States, 10708
GSK Investigational Site
Bronx, New York, United States, 10461
GSK Investigational Site
New York, New York, United States, 10009
GSK Investigational Site
New York, New York, United States, 10016
GSK Investigational Site
New York, New York, United States, 10029
GSK Investigational Site
Syracuse, New York, United States, 13210
United States, North Carolina
GSK Investigational Site
Asheville, North Carolina, United States, 28801
GSK Investigational Site
Ashville, North Carolina, United States, 28801
GSK Investigational Site
Calabash, North Carolina, United States, 28467
GSK Investigational Site
Charlotte, North Carolina, United States, 28207
GSK Investigational Site
Charlotte, North Carolina, United States, 28262
GSK Investigational Site
Charlotte, North Carolina, United States, 28277
GSK Investigational Site
Durham, North Carolina, United States, 27710
GSK Investigational Site
Elizabeth City, North Carolina, United States, 27909
GSK Investigational Site
Gastonia, North Carolina, United States, 28054
GSK Investigational Site
Greensboro, North Carolina, United States, 27403
GSK Investigational Site
Hendersonville, North Carolina, United States, 28739
GSK Investigational Site
Huntersville, North Carolina, United States, 28078
GSK Investigational Site
Lexington, North Carolina, United States, 27292
GSK Investigational Site
Mooresville, North Carolina, United States, 28117
GSK Investigational Site
Shelby, North Carolina, United States, 28150
GSK Investigational Site
Shelby, North Carolina, United States, 28152
GSK Investigational Site
Tabor City, North Carolina, United States, 28463
GSK Investigational Site
Whiteville, North Carolina, United States, 28472
GSK Investigational Site
Wilmington, North Carolina, United States, 28401
GSK Investigational Site
Winston Salem, North Carolina, United States, 27103
GSK Investigational Site
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
GSK Investigational Site
Canton, Ohio, United States, 44718
GSK Investigational Site
Cincinnati, Ohio, United States, 45220
GSK Investigational Site
Cincinnati, Ohio, United States, 45231
GSK Investigational Site
Cincinnati, Ohio, United States, 45245
GSK Investigational Site
Columbus, Ohio, United States, 43213
GSK Investigational Site
Dayton, Ohio, United States, 45459
GSK Investigational Site
Marion, Ohio, United States, 43302
GSK Investigational Site
Middleburg Heights, Ohio, United States, 44130
GSK Investigational Site
Toledo, Ohio, United States, 43606
GSK Investigational Site
Toledo, Ohio, United States, 43617
GSK Investigational Site
Wooster, Ohio, United States, 44691
United States, Oregon
GSK Investigational Site
Corvallis, Oregon, United States, 97330
GSK Investigational Site
Medford, Oregon, United States, 97504
GSK Investigational Site
Portland, Oregon, United States, 97220
GSK Investigational Site
Portland, Oregon, United States, 97225
GSK Investigational Site
Portland, Oregon, United States, 97239
United States, Pennsylvania
GSK Investigational Site
Downington, Pennsylvania, United States, 19335
GSK Investigational Site
Doylestown, Pennsylvania, United States, 18901
GSK Investigational Site
Erie, Pennsylvania, United States, 16508
GSK Investigational Site
Johnstown, Pennsylvania, United States, 15905
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19107
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19140
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19142
GSK Investigational Site
Phoenixville, Pennsylvania, United States, 19460
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15213
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15241
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15243
GSK Investigational Site
Tipton, Pennsylvania, United States, 16684
GSK Investigational Site
Wyomissing, Pennsylvania, United States, 19610
United States, Rhode Island
GSK Investigational Site
East Providence, Rhode Island, United States, 02914
United States, South Carolina
GSK Investigational Site
Anderson, South Carolina, United States, 29621
GSK Investigational Site
Charleston, South Carolina, United States, 29406-7108
GSK Investigational Site
Columbia, South Carolina, United States, 29204
GSK Investigational Site
Columbia, South Carolina, United States, 29209
GSK Investigational Site
Easley, South Carolina, United States, 29640
GSK Investigational Site
Fort Mill, South Carolina, United States, 29707
GSK Investigational Site
Gaffney, South Carolina, United States, 29340
GSK Investigational Site
Gaffney, South Carolina, United States, 29341
GSK Investigational Site
Greenville, South Carolina, United States, 29615
GSK Investigational Site
Mt. Pleasant, South Carolina, United States, 29464
GSK Investigational Site
Rock Hill, South Carolina, United States, 29732
GSK Investigational Site
Seneca, South Carolina, United States, 29678
GSK Investigational Site
Spartanburg, South Carolina, United States, 29303
GSK Investigational Site
Union, South Carolina, United States, 29379
United States, South Dakota
GSK Investigational Site
Rapid City, South Dakota, United States, 57702
GSK Investigational Site
Sioux Falls, South Dakota, United States, 57108
United States, Tennessee
GSK Investigational Site
Chattanooga, Tennessee, United States, 37404
GSK Investigational Site
Hendersonville, Tennessee, United States, 37075
GSK Investigational Site
Johnson City, Tennessee, United States, 37601
United States, Texas
GSK Investigational Site
Corsicana, Texas, United States, 75110
GSK Investigational Site
Edinburg, Texas, United States, 78539
GSK Investigational Site
Fort Worth, Texas, United States, 76104
GSK Investigational Site
Gonzales, Texas, United States, 78629
GSK Investigational Site
Houston, Texas, United States, 77030
GSK Investigational Site
Houston, Texas, United States, 77034
GSK Investigational Site
Houston, Texas, United States, 77043
GSK Investigational Site
Katy, Texas, United States, 77450
GSK Investigational Site
Kerrville, Texas, United States, 78028
GSK Investigational Site
Kingwood, Texas, United States, 77339
GSK Investigational Site
Lewisville, Texas, United States, 75067
GSK Investigational Site
Longview, Texas, United States, 75605
GSK Investigational Site
Plano, Texas, United States, 75093
GSK Investigational Site
San Antonio, Texas, United States, 78215
GSK Investigational Site
San Antonio, Texas, United States, 78229
GSK Investigational Site
Sealy, Texas, United States, 77474
GSK Investigational Site
Sugar Land, Texas, United States, 77479
GSK Investigational Site
Tomball, Texas, United States, 77375
United States, Virginia
GSK Investigational Site
Abingdon, Virginia, United States, 24210
GSK Investigational Site
Hampton, Virginia, United States, 23666
GSK Investigational Site
Lynchburg, Virginia, United States, 24501
GSK Investigational Site
Richmond, Virginia, United States, 23225
GSK Investigational Site
Richmond, Virginia, United States, 23229
GSK Investigational Site
Richmond, Virginia, United States, 23249
GSK Investigational Site
Virginia Beach, Virginia, United States, 23454
United States, Washington
GSK Investigational Site
Bellingham, Washington, United States, 98225
GSK Investigational Site
Everett, Washington, United States, 98208
GSK Investigational Site
Renton, Washington, United States, 98055
GSK Investigational Site
Renton, Washington, United States, 98057
GSK Investigational Site
Seattle, Washington, United States, 98122
GSK Investigational Site
Spokane, Washington, United States, 99204
GSK Investigational Site
Tacoma, Washington, United States, 98405
Argentina
GSK Investigational Site
Bahía Blanca, Buenos Aires, Argentina, B8000AAK
GSK Investigational Site
Caba, Buenos Aires, Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1028AAP
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1414AIF
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1425AGC
GSK Investigational Site
Florida, Buenos Aires, Argentina, 1602
GSK Investigational Site
La Plata, Buenos Aires, Argentina, 1900
GSK Investigational Site
Mar del Plata, Buenos Aires, Argentina, 7600
GSK Investigational Site
Mar del Plata, Buenos Aires, Argentina, B7600FZN
GSK Investigational Site
Nueve de Julio, Buenos Aires, Argentina, B6500BWQ
GSK Investigational Site
Paraná, Buenos Aires, Argentina, E3100BHK
GSK Investigational Site
Vicente Lopez, Buenos Aires, Argentina, B1602DOH
GSK Investigational Site
Cordoba, Córdova, Argentina, X5003DCE
GSK Investigational Site
Concepcion del Uruguay, Entre Ríos, Argentina, 3260
GSK Investigational Site
San Rafael, Mendoza, Argentina, 5600
GSK Investigational Site
Rosario, Santa Fe, Argentina, 2000
GSK Investigational Site
Rosario, Santa Fe, Argentina, S2002OJN
GSK Investigational Site
San Miguel de Tucuman, Tucumán, Argentina, 4000
GSK Investigational Site
Berazategui, Buenos Aires, Argentina, B1884AAC
GSK Investigational Site
Berazategui, Argentina, 1886
GSK Investigational Site
Buenos Aires, Argentina, C1120AAC
GSK Investigational Site
Buenos Aires, Argentina, C1424BSF
GSK Investigational Site
Buenos Aires, Argentina, C1425BEN
GSK Investigational Site
Capital Federal, Argentina, C1440BRR
GSK Investigational Site
Ciudad Autonoma de Buenis Aires, Argentina, C1015ABR
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Argentina, C1121ABE
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Argentina, C1128AAF
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Argentina, C1426ABP
GSK Investigational Site
Cordoba, Argentina, 5000
GSK Investigational Site
Coronel Suarez, Argentina, 7540
GSK Investigational Site
Mendoza, Argentina, 5500
GSK Investigational Site
Mendoza, Argentina, M5500CCG
GSK Investigational Site
Monte Grande, Argentina, 1842
GSK Investigational Site
Salta, Argentina, A4400ERH
GSK Investigational Site
San Miguel de Tucumán, Argentina, 4000
GSK Investigational Site
Santa Fe, Argentina, 3000
GSK Investigational Site
Santa Rosa, Argentina, 6300
Australia, New South Wales
GSK Investigational Site
Concord, New South Wales, Australia, 2139
GSK Investigational Site
Gosford, New South Wales, Australia, 2250
GSK Investigational Site
Maroubra, New South Wales, Australia, 2035
GSK Investigational Site
Westmead, New South Wales, Australia, 2145
Australia, Queensland
GSK Investigational Site
Cairns, Queensland, Australia, 4870
GSK Investigational Site
Carina Heights, Queensland, Australia, 4152
Australia, South Australia
GSK Investigational Site
Adelaide, South Australia, Australia, 5000
GSK Investigational Site
Daw Park, South Australia, Australia, 5041
Australia, Victoria
GSK Investigational Site
Clayton, Victoria, Australia, 3168
GSK Investigational Site
Footscray, Victoria, Australia, 3011
GSK Investigational Site
Frankston, Victoria, Australia, 3199
GSK Investigational Site
Geelong, Victoria, Australia, 3220
GSK Investigational Site
Hamilton, Victoria, Australia, 3300
Australia, Western Australia
GSK Investigational Site
Murdoch, Western Australia, Australia, 6964
GSK Investigational Site
Nedlands, Western Australia, Australia, 6009
Australia
GSK Investigational Site
Liverpool, Australia, 2107
Austria
GSK Investigational Site
Feldbach, Austria, 8330
GSK Investigational Site
Feldkirch, Austria, 6800
GSK Investigational Site
Grieskirchen, Austria, A-4710
GSK Investigational Site
Thalheim bei Wels, Austria, 4600
GSK Investigational Site
Vienna, Austria, A-1030
Belgium
GSK Investigational Site
Antwerpen, Belgium, 2060
GSK Investigational Site
Brugge, Belgium, 8000
GSK Investigational Site
Brussels, Belgium, 1200
GSK Investigational Site
Erpent, Belgium, 5101
GSK Investigational Site
Genk, Belgium, 3600
GSK Investigational Site
Gent, Belgium, 9000
GSK Investigational Site
Gilly, Belgium, 6060
GSK Investigational Site
Hasselt, Belgium, 3500
GSK Investigational Site
Liège, Belgium, 4000
GSK Investigational Site
Malmedy, Belgium, 4960
GSK Investigational Site
Mechelen, Belgium, 2800
GSK Investigational Site
Montigny-Le-Tilleul, Belgium, 6110
GSK Investigational Site
Oostende, Belgium, 8400
GSK Investigational Site
Roeselaere, Belgium, 8800
GSK Investigational Site
Turnhout, Belgium, 2300
Brazil
GSK Investigational Site
Recife, Pernambuco, Brazil, 50920-900
GSK Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-074
GSK Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90480-000
GSK Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90610000
GSK Investigational Site
Blumenau, Santa Catarina, Brazil, 89030-101
GSK Investigational Site
Florianopolis, Santa Catarina, Brazil, 88040-970
GSK Investigational Site
Rio de Janeiro, Brazil, 21941-913
GSK Investigational Site
São Paulo, Brazil, 01323903
GSK Investigational Site
São Paulo, Brazil, 04023900
GSK Investigational Site
São Paulo, Brazil, 04266-010
GSK Investigational Site
São Paulo, Brazil, 05403-000
Canada, Alberta
GSK Investigational Site
Edmonton, Alberta, Canada, T6G 2G3
GSK Investigational Site
Sherwood Park, Alberta, Canada, T8H 0N2
Canada, Manitoba
GSK Investigational Site
Winnipeg, Manitoba, Canada, R2H 2A6
GSK Investigational Site
Winnipeg, Manitoba, Canada, R2K 3S8
Canada, New Brunswick
GSK Investigational Site
Moncton, New Brunswick, Canada, E1G 2K5
Canada, Nova Scotia
GSK Investigational Site
Truro, Nova Scotia, Canada, B2N 1L2
Canada, Ontario
GSK Investigational Site
Burlington, Ontario, Canada, L7N 3V2
GSK Investigational Site
Cornwall, Ontario, Canada, K6H4M4
GSK Investigational Site
Hamilton, Ontario, Canada, L8L 5G8
GSK Investigational Site
Hamilton, Ontario, Canada, L8N 3Z5
GSK Investigational Site
Sarnia, Ontario, Canada, N7T 4X3
GSK Investigational Site
Sudbury, Ontario, Canada, P3A 1Y8
GSK Investigational Site
Sudbury, Ontario, Canada, P3E 1H5
GSK Investigational Site
Toronto, Ontario, Canada, M3J 2C5
GSK Investigational Site
Toronto, Ontario, Canada, M4S 1Y2
GSK Investigational Site
Toronto, Ontario, Canada, M5T 3A9
GSK Investigational Site
Toronto, Ontario, Canada, M9C 4Z5
GSK Investigational Site
Toronto, Ontario, Canada, M9W 4L6
GSK Investigational Site
Windsor, Ontario, Canada, N8X 5A6
Canada, Quebec
GSK Investigational Site
Gatineau, Quebec, Canada, J8Y 6S8
GSK Investigational Site
Mirabel, Quebec, Canada, J7J 2K8
GSK Investigational Site
Montréal, Quebec, Canada, H1M 1B1
GSK Investigational Site
St-Charles-Borromée, Quebec, Canada, J6E 2B4
GSK Investigational Site
Trois Rivieres, Quebec, Canada, G8T 7A1
Canada
GSK Investigational Site
Quebec, Canada, G1V 4G5
GSK Investigational Site
Quebec, Canada, G3K 2P8
Chile
GSK Investigational Site
Concepción, Región Del Biobio, Chile, 4070038
GSK Investigational Site
Curicó, Región Del Maule, Chile, 3341643
GSK Investigational Site
Talca, Región Del Maule, Chile, 3465584
GSK Investigational Site
Puente Alto - Santiago, Región Metro De Santiago, Chile, 8207257
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 7500692
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 7500710
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 7510186
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 7860406
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 8360160
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 8910131
GSK Investigational Site
Valparaiso, Valparaíso, Chile, 2341131
GSK Investigational Site
Viña del Mar, Valparaíso, Chile, 2520024
GSK Investigational Site
Santiago, Chile, 7500698
GSK Investigational Site
Santiago, Chile, 8380453
GSK Investigational Site
Talcahuano, Chile, 4270918
GSK Investigational Site
Viña del Mar, Chile, 2520594
China, Guangdong
GSK Investigational Site
Guangzhou, Guangdong, China, 510080
GSK Investigational Site
Guangzhou, Guangdong, China, 510120
GSK Investigational Site
Guangzhou, Guangdong, China, 510150
GSK Investigational Site
Guangzhou, Guangdong, China, 510180
GSK Investigational Site
Guangzhou, Guangdong, China, 510630
GSK Investigational Site
Zhanjiang, Guangdong, China, 524001
China, Guangxi
GSK Investigational Site
Nanning, Guangxi, China, 530021
China, Hainan
GSK Investigational Site
Haikou, Hainan, China, 570311
China, Hebei
GSK Investigational Site
Shijiazhuang, Hebei, China, 050000
China, Jiangsu
GSK Investigational Site
Nanjing, Jiangsu, China, 210006
GSK Investigational Site
Nanjing, Jiangsu, China, 210008
GSK Investigational Site
Nanjing, Jiangsu, China, 210029
China, Jiangxi
GSK Investigational Site
Nanchang, Jiangxi, China, 330006
China, Jilin
GSK Investigational Site
Changchun, Jilin, China, 130041
China, Liaoning
GSK Investigational Site
Shenyang, Liaoning, China, 110004
GSK Investigational Site
Shenyang, Liaoning, China, 110015
China, Ningxia
GSK Investigational Site
Yinchuan, Ningxia, China, 750004
China, Shandong
GSK Investigational Site
Jinan, Shandong, China, 250012
GSK Investigational Site
Jinan, Shandong, China, 250013
GSK Investigational Site
Qingdao, Shandong, China, 266071
China, Shanxi
GSK Investigational Site
Taiyuan, Shanxi, China, 030001
GSK Investigational Site
Xian, Shanxi, China, 710032
China, Sichuan
GSK Investigational Site
Chengdu, Sichuan, China, 610041
China, Zhejiang
GSK Investigational Site
Hangzhou, Zhejiang, China
China
GSK Investigational Site
Beijing, China, 100020
GSK Investigational Site
Beijing, China, 100029
GSK Investigational Site
Beijing, China, 100034
GSK Investigational Site
Beijing, China, 100050
GSK Investigational Site
Beijing, China, 100191
GSK Investigational Site
Changsha, China, 410013
GSK Investigational Site
Chongqing, China, 400037
GSK Investigational Site
Chongqing, China, 400038
GSK Investigational Site
Chongqing, China
GSK Investigational Site
Fuzhou, China, 350025
GSK Investigational Site
Guangzhou, China, 510080
GSK Investigational Site
Nanchang, China, 330006
GSK Investigational Site
Shanghai, China, 200025
GSK Investigational Site
Shanghai, China, 200433
GSK Investigational Site
Tianjin, China, 300052
GSK Investigational Site
Wuxi, China, 214023
Colombia
GSK Investigational Site
Barranquilla, Colombia
GSK Investigational Site
Bogota, Colombia
GSK Investigational Site
Bogotá, Colombia, 80CO
GSK Investigational Site
Bogotá, Colombia
GSK Investigational Site
Medellin, Colombia
Czech Republic
GSK Investigational Site
Benesov, Czech Republic, 256 30
GSK Investigational Site
Brandys nad Labem, Czech Republic, 250 01
GSK Investigational Site
Cvikov, Czech Republic, 471 54
GSK Investigational Site
Holesov, Czech Republic, 769 01
GSK Investigational Site
Hradec Kralove, Czech Republic, 500 05
GSK Investigational Site
Jaromer, Czech Republic, 551 01
GSK Investigational Site
Olomouc, Czech Republic, 772 00
GSK Investigational Site
Olomouc, Czech Republic, 775 20
GSK Investigational Site
Ostrava - Poruba, Czech Republic, 70868
GSK Investigational Site
Plzen, Czech Republic, 301 00
GSK Investigational Site
Praha 5, Czech Republic, 150 06
GSK Investigational Site
Praha 8, Czech Republic, 182 00
GSK Investigational Site
Tabor, Czech Republic, 390 19
GSK Investigational Site
Teplice, Czech Republic, 415 10
GSK Investigational Site
Trebic, Czech Republic, 674 01
Denmark
GSK Investigational Site
Aalborg, Denmark, 9100
GSK Investigational Site
Aarhus C, Denmark, 8000
GSK Investigational Site
Hellerup, Denmark, 2900
GSK Investigational Site
Hvidovre, Denmark, 2650
GSK Investigational Site
Kolding, Denmark, DK-6000
GSK Investigational Site
Odense C, Denmark, 5000
GSK Investigational Site
Roskilde, Denmark, 4000
GSK Investigational Site
Sønderborg, Denmark, 6400
Finland
GSK Investigational Site
Espoo, Finland, 02740
GSK Investigational Site
Helsinki, Finland, 00290
GSK Investigational Site
Jyvaskyla, Finland, 40100
GSK Investigational Site
Lohja, Finland, 08200
GSK Investigational Site
Tampere, Finland, 33520
GSK Investigational Site
Turku, Finland, 20100
GSK Investigational Site
Turku, Finland, 20520
France
GSK Investigational Site
Bayonne cedex, France, 64109
GSK Investigational Site
Brest Cedex, France, 29609
GSK Investigational Site
Briis-sous-Forge, France, 91640
GSK Investigational Site
Grenoble cedex 9, France, 38043
GSK Investigational Site
Le Mans, France, 72000
GSK Investigational Site
Lyon cedex 04, France, 69317
GSK Investigational Site
Marseille cedex 03, France, 13331
GSK Investigational Site
Montauban cedex, France, 82017
GSK Investigational Site
Montpellier cedex 5, France, 34295
GSK Investigational Site
Nimes, France, 30900
GSK Investigational Site
Orléans cedex 2, France, 45067
GSK Investigational Site
Paris, France, 75014
GSK Investigational Site
Perpignan, France, 66000
GSK Investigational Site
Pessac cedex, France, 33604
GSK Investigational Site
Pringy cedex, France, 74374
GSK Investigational Site
Rennes Cedex 9, France, 35033
GSK Investigational Site
Strasbourg cedex, France, 67091
GSK Investigational Site
Toulon, France, 83000
GSK Investigational Site
Vandoeuvre-les-Nancy, France, 54511
Germany
GSK Investigational Site
Deggingen, Baden-Wuerttemberg, Germany, 73326
GSK Investigational Site
Leonberg, Baden-Wuerttemberg, Germany, 71229
GSK Investigational Site
Mannheim, Baden-Wuerttemberg, Germany, 68161
GSK Investigational Site
Mannheim, Baden-Wuerttemberg, Germany, 68167
GSK Investigational Site
Stuttgart, Baden-Wuerttemberg, Germany, 70372
GSK Investigational Site
Stuttgart, Baden-Wuerttemberg, Germany, 70378
GSK Investigational Site
Wiesloch, Baden-Wuerttemberg, Germany, 69168
GSK Investigational Site
Aschaffenburg, Bayern, Germany, 63739
GSK Investigational Site
Augsburg, Bayern, Germany, 86150
GSK Investigational Site
Bad Woerrishofen, Bayern, Germany, 86825
GSK Investigational Site
Bamberg, Bayern, Germany, 96049
GSK Investigational Site
Dachau, Bayern, Germany, 85221
GSK Investigational Site
Dillingen, Bayern, Germany, 89407
GSK Investigational Site
Donaustauf, Bayern, Germany, 93093
GSK Investigational Site
Garmisch-Partenirchen, Bayern, Germany, 82467
GSK Investigational Site
Gauting, Bayern, Germany, 82131
GSK Investigational Site
Landsberg, Bayern, Germany, 86899
GSK Investigational Site
Muenchen, Bayern, Germany, 80339
GSK Investigational Site
Muenchen, Bayern, Germany, 80539
GSK Investigational Site
Neu-Ulm, Bayern, Germany, 89231
GSK Investigational Site
Nuernberg, Bayern, Germany, 90402
GSK Investigational Site
Rosenheim, Bayern, Germany, 83022
GSK Investigational Site
Wallerfing, Bayern, Germany, 94574
GSK Investigational Site
Cottbus, Brandenburg, Germany, 03050
GSK Investigational Site
Potsdam, Brandenburg, Germany, 14467
GSK Investigational Site
Potsdam, Brandenburg, Germany, 14469
GSK Investigational Site
Rathenow, Brandenburg, Germany, 14712
GSK Investigational Site
Ruedersdorf, Brandenburg, Germany, 15562
GSK Investigational Site
Bensheim, Hessen, Germany, 64625
GSK Investigational Site
Frankenberg, Hessen, Germany, 35066
GSK Investigational Site
Frankfurt, Hessen, Germany, 60389
GSK Investigational Site
Frankfurt, Hessen, Germany, 60596
GSK Investigational Site
Fuldatal, Hessen, Germany, 34233
GSK Investigational Site
Fulda, Hessen, Germany, 36039
GSK Investigational Site
Kassel, Hessen, Germany, 34121
GSK Investigational Site
Marburg, Hessen, Germany, 35037
GSK Investigational Site
Neu isenburg, Hessen, Germany, 63263
GSK Investigational Site
Offenbach, Hessen, Germany, 63071
GSK Investigational Site
Rodgau, Hessen, Germany, 63110
GSK Investigational Site
Ruesselsheim, Hessen, Germany, 65428
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30167
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30173
GSK Investigational Site
Peine, Niedersachsen, Germany, 31224
GSK Investigational Site
Wardenburg, Niedersachsen, Germany, 26203
GSK Investigational Site
Bad Lippspringe, Nordrhein-Westfalen, Germany, 33175
GSK Investigational Site
Bergisch Gladbach, Nordrhein-Westfalen, Germany, 51429
GSK Investigational Site
Bonn, Nordrhein-Westfalen, Germany, 53119
GSK Investigational Site
Bonn, Nordrhein-Westfalen, Germany, 53123
GSK Investigational Site
Dortmund, Nordrhein-Westfalen, Germany, 44263
GSK Investigational Site
Dueren, Nordrhein-Westfalen, Germany, 52349
GSK Investigational Site
Duisburg, Nordrhein-Westfalen, Germany, 47057
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45277
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45355
GSK Investigational Site
Freudenberg, Nordrhein-Westfalen, Germany, 57258
GSK Investigational Site
Gelsenkirchen, Nordrhein-Westfalen, Germany, 45879
GSK Investigational Site
Gummersbach, Nordrhein-Westfalen, Germany, 51643
GSK Investigational Site
Hagen, Nordrhein-Westfalen, Germany, 58089
GSK Investigational Site
Kleve, Nordrhein-Westfalen, Germany, 47533
GSK Investigational Site
Koeln, Nordrhein-Westfalen, Germany, 51065
GSK Investigational Site
Neuss, Nordrhein-Westfalen, Germany, 41462
GSK Investigational Site
Ratingen, Nordrhein-Westfalen, Germany, 40878
GSK Investigational Site
Rheine, Nordrhein-Westfalen, Germany, 48431
GSK Investigational Site
Solingen, Nordrhein-Westfalen, Germany, 42699
GSK Investigational Site
Warendorf, Nordrhein-Westfalen, Germany, 48231
GSK Investigational Site
Witten, Nordrhein-Westfalen, Germany, 58452
GSK Investigational Site
Bernkastel-Kues, Rheinland-Pfalz, Germany, 54470
GSK Investigational Site
Koblenz, Rheinland-Pfalz, Germany, 56068
GSK Investigational Site
Mainz, Rheinland-Pfalz, Germany, 55116
GSK Investigational Site
Neuwied, Rheinland-Pfalz, Germany, 56564
GSK Investigational Site
Wissen, Rheinland-Pfalz, Germany, 57537
GSK Investigational Site
Saarbruecken, Saarland, Germany, 66111
GSK Investigational Site
Halberstadt, Sachsen-Anhalt, Germany, 38820
GSK Investigational Site
Halle, Sachsen-Anhalt, Germany, 06108
GSK Investigational Site
Hettstedt, Sachsen-Anhalt, Germany, 06333
GSK Investigational Site
Teuchern, Sachsen-Anhalt, Germany, 06682
GSK Investigational Site
Zerbst, Sachsen-Anhalt, Germany, 39261
GSK Investigational Site
Auerbach, Sachsen, Germany, 08209
GSK Investigational Site
Delitzsch, Sachsen, Germany, 04509
GSK Investigational Site
Leipzg, Sachsen, Germany, 04109
GSK Investigational Site
Leipzig, Sachsen, Germany, 04103
GSK Investigational Site
Leipzig, Sachsen, Germany, 04157
GSK Investigational Site
Leipzig, Sachsen, Germany, 04275
GSK Investigational Site
Leipzig, Sachsen, Germany, 04357
GSK Investigational Site
Geesthacht, Schleswig-Holstein, Germany, 21502
GSK Investigational Site
Luebeck, Schleswig-Holstein, Germany, 23558
GSK Investigational Site
Reinfeld, Schleswig-Holstein, Germany, 23858
GSK Investigational Site
Schleswig, Schleswig-Holstein, Germany, 24837
GSK Investigational Site
Gera, Thueringen, Germany, 07548
GSK Investigational Site
Saalfeld, Thueringen, Germany, 07318
GSK Investigational Site
Schmoelln, Thueringen, Germany, 04626
GSK Investigational Site
Berlin, Germany, 10119
GSK Investigational Site
Berlin, Germany, 10247
GSK Investigational Site
Berlin, Germany, 10367
GSK Investigational Site
Berlin, Germany, 10625
GSK Investigational Site
Berlin, Germany, 10717
GSK Investigational Site
Berlin, Germany, 10961
GSK Investigational Site
Berlin, Germany, 10969
GSK Investigational Site
Berlin, Germany, 12043
GSK Investigational Site
Berlin, Germany, 12157
GSK Investigational Site
Berlin, Germany, 12159
GSK Investigational Site
Berlin, Germany, 12203
GSK Investigational Site
Berlin, Germany, 12627
GSK Investigational Site
Berlin, Germany, 13057
GSK Investigational Site
Berlin, Germany, 13086
GSK Investigational Site
Berlin, Germany, 13156
GSK Investigational Site
Berlin, Germany, 13187
GSK Investigational Site
Berlin, Germany, 13353
GSK Investigational Site
Berlin, Germany, 13507
GSK Investigational Site
Berlin, Germany, 13581
GSK Investigational Site
Berlin, Germany, 14059
GSK Investigational Site
Deggendorf, Germany, 94469
GSK Investigational Site
Hamburg, Germany, 22291
GSK Investigational Site
Hamburg, Germany, 22299
GSK Investigational Site
Hamburg, Germany, 22763
GSK Investigational Site
Witten, Germany, 58452
Hong Kong
GSK Investigational Site
Kwun Tong, Hong Kong
GSK Investigational Site
Lai Chi Kok, Hong Kong
GSK Investigational Site
Pokfulam, Hong Kong
GSK Investigational Site
Shatin, Hong Kong
GSK Investigational Site
Tuen Mun, Hong Kong
Israel
GSK Investigational Site
Afula, Israel, 18101
GSK Investigational Site
Ashkelon, Israel, 78360
GSK Investigational Site
Haifa, Israel, 34362
GSK Investigational Site
Holon, Israel, 58100
GSK Investigational Site
Jerusalem, Israel, 91031
GSK Investigational Site
Jerusalem, Israel, 91120
GSK Investigational Site
Kfar-Saba, Israel, 44281
GSK Investigational Site
Petah Tikva, Israel, 49100
GSK Investigational Site
Ramat Gan, Israel, 52621
GSK Investigational Site
Rehovot, Israel, 76100
GSK Investigational Site
Tel Aviv, Israel, 67891
GSK Investigational Site
Tel-Aviv, Israel, 64239
GSK Investigational Site
Zrifin, Israel, 70300
Japan
GSK Investigational Site
Aichi, Japan, 455-8530
GSK Investigational Site
Aichi, Japan, 457-8510
GSK Investigational Site
Aichi, Japan, 457-8511
GSK Investigational Site
Aichi, Japan, 460-0001
GSK Investigational Site
Aichi, Japan, 471-8513
GSK Investigational Site
Aichi, Japan, 485-0041
GSK Investigational Site
Aichi, Japan, 489-8642
GSK Investigational Site
Chiba, Japan, 278-0004
GSK Investigational Site
Chiba, Japan, 296-8602
GSK Investigational Site
Ehime, Japan, 791-0281
GSK Investigational Site
Fukuoka, Japan, 802-0052
GSK Investigational Site
Fukuoka, Japan, 802-0083
GSK Investigational Site
Fukuoka, Japan, 811-1394
GSK Investigational Site
Fukuoka, Japan, 816-0813
GSK Investigational Site
Fukuoka, Japan, 820-8505
GSK Investigational Site
Fukuoka, Japan, 832-0059
GSK Investigational Site
Gifu, Japan, 500-8717
GSK Investigational Site
Gifu, Japan, 506-8550
GSK Investigational Site
Gifu, Japan, 509-6134
GSK Investigational Site
Gunma, Japan, 372-0831
GSK Investigational Site
Gunma, Japan, 373-0807
GSK Investigational Site
Hiroshima, Japan, 722-8503
GSK Investigational Site
Hiroshima, Japan, 734-8530
GSK Investigational Site
Hiroshima, Japan, 735-8585
GSK Investigational Site
Hokkaido, Japan, 001-0901
GSK Investigational Site
Hokkaido, Japan, 053-8506
GSK Investigational Site
Hokkaido, Japan, 060-0033
GSK Investigational Site
Hokkaido, Japan, 062-8618
GSK Investigational Site
Hokkaido, Japan, 063-0005
GSK Investigational Site
Hokkaido, Japan, 064-0801
GSK Investigational Site
Hokkaido, Japan, 064-0915
GSK Investigational Site
Hokkaido, Japan, 070-8644
GSK Investigational Site
Hokkaido, Japan, 071-8132
GSK Investigational Site
Hokkaido, Japan, 078-8211
GSK Investigational Site
Hokkaido, Japan, 080-0805
GSK Investigational Site
Hyogo, Japan, 650-0047
GSK Investigational Site
Hyogo, Japan, 651-0072
GSK Investigational Site
Hyogo, Japan, 653-0013
GSK Investigational Site
Hyogo, Japan, 664-8540
GSK Investigational Site
Hyogo, Japan, 670-0849
GSK Investigational Site
Hyogo, Japan, 672-8064
GSK Investigational Site
Hyogo, Japan, 674-0063
GSK Investigational Site
Hyogo, Japan, 675-8611
GSK Investigational Site
Ibaraki, Japan, 302-0022
GSK Investigational Site
Ibaraki, Japan, 310-0015
GSK Investigational Site
Ibaraki, Japan, 311-3193
GSK Investigational Site
Ibaraki, Japan, 317-0077
GSK Investigational Site
Ibaraki, Japan, 319-1113
GSK Investigational Site
Ishikawa, Japan, 920-8530
GSK Investigational Site
Ishikawa, Japan, 920-8610
GSK Investigational Site
Ishikawa, Japan, 921-8105
GSK Investigational Site
Ishikawa, Japan, 923-8560
GSK Investigational Site
Iwate, Japan, 020-0055
GSK Investigational Site
Kagawa, Japan, 760-0018
GSK Investigational Site
Kagawa, Japan, 760-8538
GSK Investigational Site
Kagawa, Japan, 761-8073
GSK Investigational Site
Kagawa, Japan, 762-8550
GSK Investigational Site
Kanagawa, Japan, 210-0852
GSK Investigational Site
Kanagawa, Japan, 232-0024
GSK Investigational Site
Kanagawa, Japan, 232-0066
GSK Investigational Site
Kanagawa, Japan, 239-0821
GSK Investigational Site
Kanagawa, Japan, 252-5188
GSK Investigational Site
Kanagawa, Japan, 254-8502
GSK Investigational Site
Kochi, Japan, 780-8077
GSK Investigational Site
Kumamoto, Japan, 861-1196
GSK Investigational Site
Kyoto, Japan, 601-1495
GSK Investigational Site
Kyoto, Japan, 607-8062
GSK Investigational Site
Kyoto, Japan, 615-8087
GSK Investigational Site
Mie, Japan, 510-8567
GSK Investigational Site
Mie, Japan, 515-8544
GSK Investigational Site
Miyagi, Japan, 984-8560
GSK Investigational Site
Miyagi, Japan, 985-8506
GSK Investigational Site
Miyagi, Japan, 986-8522
GSK Investigational Site
Miyagi, Japan, 989-1253
GSK Investigational Site
Nagano, Japan, 392-8510
GSK Investigational Site
Niigata, Japan, 940-0856
GSK Investigational Site
Oita, Japan, 870-0921
GSK Investigational Site
Okayama, Japan, 701-0304
GSK Investigational Site
Okayama, Japan, 702-8055
GSK Investigational Site
Okayama, Japan, 711-0921
GSK Investigational Site
Okinawa, Japan, 901-2121
GSK Investigational Site
Okinawa, Japan, 901-2132
GSK Investigational Site
Okinawa, Japan, 901-2393
GSK Investigational Site
Okinawa, Japan, 904-2143
GSK Investigational Site
Okinawa, Japan, 904-2293
GSK Investigational Site
Osaka, Japan, 530-0001
GSK Investigational Site
Osaka, Japan, 533-0024
GSK Investigational Site
Osaka, Japan, 559-0012
GSK Investigational Site
Osaka, Japan, 564-0013
GSK Investigational Site
Osaka, Japan, 576-0016
GSK Investigational Site
Osaka, Japan, 576-0041
GSK Investigational Site
Osaka, Japan, 591-8037
GSK Investigational Site
Osaka, Japan, 591-8555
GSK Investigational Site
Osaka, Japan, 596-8501
GSK Investigational Site
Saitama, Japan, 349-1105
GSK Investigational Site
Shizuoka, Japan, 420-8527
GSK Investigational Site
Shizuoka, Japan, 430-8525
GSK Investigational Site
Tochigi, Japan, 320-0065
GSK Investigational Site
Tokyo, Japan, 103-0027
GSK Investigational Site
Tokyo, Japan, 103-0028
GSK Investigational Site
Tokyo, Japan, 104-8560
GSK Investigational Site
Tokyo, Japan, 120-0033
GSK Investigational Site
Tokyo, Japan, 134-0083
GSK Investigational Site
Tokyo, Japan, 158-8531
GSK Investigational Site
Tokyo, Japan, 194-0023
GSK Investigational Site
Tokyo, Japan, 198-0042
GSK Investigational Site
Tokyo, Japan, 204-8585
GSK Investigational Site
Toyama, Japan, 937-0042
GSK Investigational Site
Toyama, Japan, 938-8502
GSK Investigational Site
Wakayama, Japan, 640-8558
GSK Investigational Site
Yamagata, Japan, 990-8533
GSK Investigational Site
Yamanashi, Japan, 400-0031
GSK Investigational Site
Yamanashi, Japan, 400-8506
Korea, Republic of
GSK Investigational Site
Bucheon city, Gyenggi-do, Korea, Republic of, 420-767
GSK Investigational Site
Cheongju-si, Chungcheongbuk-do, Korea, Republic of, 361-763
GSK Investigational Site
Gyeonggi-do, Korea, Republic of, 410-719
GSK Investigational Site
Gyeonggi-do, Korea, Republic of, 431-796
GSK Investigational Site
Gyeonggi-do, Korea, Republic of, 463-707
GSK Investigational Site
Incheon, Korea, Republic of, 403-720
GSK Investigational Site
Incheon, Korea, Republic of, 405-760
GSK Investigational Site
Jeonju-si, Korea, Republic of, 561-712
GSK Investigational Site
Kangwon-do, Korea, Republic of, 220-701
GSK Investigational Site
Seoul, Korea, Republic of, 110-744
GSK Investigational Site
Seoul, Korea, Republic of, 120-752
GSK Investigational Site
Seoul, Korea, Republic of, 130-709
GSK Investigational Site
Seoul, Korea, Republic of, 130-872
GSK Investigational Site
Seoul, Korea, Republic of, 134-791
GSK Investigational Site
Seoul, Korea, Republic of, 134-814
GSK Investigational Site
Seoul, Korea, Republic of, 135-720
GSK Investigational Site
Seoul, Korea, Republic of, 136-705
GSK Investigational Site
Seoul, Korea, Republic of, 143-729
GSK Investigational Site
Seoul, Korea, Republic of, 150-713
GSK Investigational Site
Seoul, Korea, Republic of, 156-707
GSK Investigational Site
Seoul, Korea, Republic of, 156-755
GSK Investigational Site
Seoul, Korea, Republic of, 158-710
GSK Investigational Site
Suwon, Korea, Republic of, 442-723
Netherlands
GSK Investigational Site
Alkmaar, Netherlands, 1815 JD
GSK Investigational Site
Almelo, Netherlands, 7606 SB
GSK Investigational Site
Almelo, Netherlands, 7609 PP
GSK Investigational Site
Assen, Netherlands, 9401 RK
GSK Investigational Site
Beek, Netherlands, 6191 JW
GSK Investigational Site
Breda, Netherlands, 4818 CK
GSK Investigational Site
Den Bosch, Netherlands, 5211 NL
GSK Investigational Site
Dordrecht, Netherlands, 3318 AT
GSK Investigational Site
Eindhoven, Netherlands, 5623 EJ
GSK Investigational Site
Enschede, Netherlands, 7513 ER
GSK Investigational Site
Groningen, Netherlands, 9728 NT
GSK Investigational Site
Harderwijk, Netherlands, 3844 DG
GSK Investigational Site
Helmond, Netherlands, 5707 HA
GSK Investigational Site
Hoofddorp, Netherlands, 2134 TM
GSK Investigational Site
Hoorn, Netherlands, 1624 NP
GSK Investigational Site
Kloosterhaar, Netherlands, 7694 AC
GSK Investigational Site
Leeuwarden, Netherlands, 8934 AD
GSK Investigational Site
Nieuwegein, Netherlands, 3435 CM
GSK Investigational Site
Rotterdam, Netherlands, 3083 AN
GSK Investigational Site
Sneek, Netherlands, 8601 ZR
GSK Investigational Site
Spijkenisse, Netherlands, 3207 NB
GSK Investigational Site
Veldhoven, Netherlands, 5504 DB
GSK Investigational Site
Zutphen, Netherlands, 7207 AE
GSK Investigational Site
Zwolle, Netherlands, 8025 AB
New Zealand
GSK Investigational Site
Auckland, New Zealand, 1051
GSK Investigational Site
Dunedin, New Zealand, 9012
GSK Investigational Site
Newtown, Wellington, New Zealand, 6021
GSK Investigational Site
Tauranga, New Zealand, 3110
GSK Investigational Site
Tauranga, New Zealand, 3112
GSK Investigational Site
Wellington, New Zealand, 6021
Norway
GSK Investigational Site
Bodø, Norway, 8005
GSK Investigational Site
Fredrikstad, Norway, 1606
GSK Investigational Site
Hakadal, Norway, 1487
GSK Investigational Site
Kløfta, Norway, 2040
GSK Investigational Site
Levanger, Norway, 7600
GSK Investigational Site
Oslo, Norway, 0953
GSK Investigational Site
Stavanger, Norway, 4005
GSK Investigational Site
Stavanger, Norway, 4011
GSK Investigational Site
Trondheim, Norway, 7027
Peru
GSK Investigational Site
Pueblo Libre, Lima, Peru, Lima 21
GSK Investigational Site
San Martin de Porres, Lima, Peru, Lima 31
GSK Investigational Site
San Miguel, Lima, Peru, Lima 32
GSK Investigational Site
Lima, Peru, 01
GSK Investigational Site
Lima, Peru, L 33
GSK Investigational Site
Lima, Peru, L41
GSK Investigational Site
Lima, Peru, Lima 14
GSK Investigational Site
Lima, Peru, Lima 18
GSK Investigational Site
Lima, Peru, Lima 1
GSK Investigational Site
Lima, Peru, Lima 27
GSK Investigational Site
Lima, Peru, Lima 32
GSK Investigational Site
Lima, Peru, Lima 47
Philippines
GSK Investigational Site
Caloocan City, Philippines, 1400
GSK Investigational Site
Iloilo, Philippines, 5000
GSK Investigational Site
Jaro, Iloilo City, Philippines, 5000
GSK Investigational Site
Pasig, Philippines, 1605
GSK Investigational Site
Quezon City, Philippines, 1100
Poland
GSK Investigational Site
Bialystok, Poland, 15-354
GSK Investigational Site
Ostrowiec Swietokrzyski, Poland, 27-400
GSK Investigational Site
Sopot, Poland, 81-741
GSK Investigational Site
Szczecin, Poland, 71-124
GSK Investigational Site
Tarnów, Poland, 33-100
GSK Investigational Site
Zgierz, Poland, 95-100
Puerto Rico
GSK Investigational Site
Guaynabo, Puerto Rico, 00968
GSK Investigational Site
Mayaguez, Puerto Rico, 00680
GSK Investigational Site
Ponce, Puerto Rico, 00716
GSK Investigational Site
San Juan, Puerto Rico, 00921
GSK Investigational Site
San Juan, Puerto Rico, 00927
Romania
GSK Investigational Site
Braila, Romania, 810003
GSK Investigational Site
Brasov, Romania, 500283
GSK Investigational Site
Bucharest, Romania, 020125
GSK Investigational Site
Comuna Alexandru cel Bun, Romania, 617507
GSK Investigational Site
Constanta, Romania, 900002
GSK Investigational Site
Ploiesti, Romania, 100184
GSK Investigational Site
Ploiesti, Romania, 100379
GSK Investigational Site
Ramnicu Valcea, Romania, 240564
Russian Federation
GSK Investigational Site
Barnaul, Russian Federation, 656038
GSK Investigational Site
Belgorod, Russian Federation, 308007
GSK Investigational Site
Blagoveshchensk, Russian Federation, 675000
GSK Investigational Site
Chita, Russian Federation, 672000
GSK Investigational Site
Chita, Russian Federation, 672090
GSK Investigational Site
Ekaterinburg, Russian Federation, 620109
GSK Investigational Site
Ivanovo, Russian Federation, 153005
GSK Investigational Site
Kazan, Russian Federation, 420012
GSK Investigational Site
Kazan, Russian Federation, 420015
GSK Investigational Site
Krasnodar, Russian Federation, 350012
GSK Investigational Site
Krasnoyarsk, Russian Federation, 660022
GSK Investigational Site
Moscow, Russian Federation, 119002
GSK Investigational Site
Moscow, Russian Federation, 127018
GSK Investigational Site
Novgorod, Russian Federation, 173008
GSK Investigational Site
Novosibirsk, Russian Federation, 630087
GSK Investigational Site
Petrozavodsk, Russian Federation, 185019
GSK Investigational Site
Pyatigorsk, Russian Federation, 357538
GSK Investigational Site
Ryazan, Russian Federation, 390005
GSK Investigational Site
Ryazan, Russian Federation, 390039
GSK Investigational Site
Saint-Petersburg, Russian Federation, 194354
GSK Investigational Site
Saratov, Russian Federation, 410053
GSK Investigational Site
St. Petersburg, Russian Federation, 194356
GSK Investigational Site
St. Petersburg, Russian Federation, 198216
GSK Investigational Site
Stavropol, Russian Federation, 355017
GSK Investigational Site
Tomsk, Russian Federation, 634009
GSK Investigational Site
Tomsk, Russian Federation, 634050
GSK Investigational Site
Ulan-Ude, Russian Federation, 670031
GSK Investigational Site
Ulyanovsk, Russian Federation, 432063
GSK Investigational Site
Vladimir, Russian Federation, 600023
GSK Investigational Site
Vladivostok, Russian Federation, 690002
GSK Investigational Site
Vladivostok, Russian Federation, 690950
GSK Investigational Site
Volgodonsk, Russian Federation, 347381
GSK Investigational Site
Voronezh, Russian Federation, 394066
GSK Investigational Site
Vsevolozhsk, Leningrad Region, Russian Federation, 188640
GSK Investigational Site
Yaroslavl, Russian Federation, 150003
GSK Investigational Site
Yaroslavl, Russian Federation, 150010
Singapore
GSK Investigational Site
Singapore, Singapore, 117599
GSK Investigational Site
Singapore, Singapore, 169856
GSK Investigational Site
Singapore, Singapore, 529889
GSK Investigational Site
Singapore, Singapore, 609606
South Africa
GSK Investigational Site
Benoni, Gauteng, South Africa, 1501
GSK Investigational Site
Boksburg, Gauteng, South Africa, 1459
GSK Investigational Site
Pretoria, Gauteng, South Africa, 0183
GSK Investigational Site
Val de Grace, Pretoria, Gauteng, South Africa, 0184
GSK Investigational Site
Middelburg, Mpumalanga, South Africa, 1055
GSK Investigational Site
Amanzimtoti, South Africa, 4126
GSK Investigational Site
Bellville, South Africa, 7530
GSK Investigational Site
Bloemfontein, South Africa, 9301
GSK Investigational Site
Boksburg North, South Africa, 1459
GSK Investigational Site
Cape Town, South Africa, 7129
GSK Investigational Site
Cape Town, South Africa, 7572
GSK Investigational Site
CapeTown, South Africa, 7764
GSK Investigational Site
Durban, South Africa, 4001
GSK Investigational Site
Durban, South Africa, 4091
GSK Investigational Site
Gatesville, South Africa, 7764
GSK Investigational Site
Johannesburg, South Africa, 2113
GSK Investigational Site
Korsten, South Africa, 6014
GSK Investigational Site
Mowbray, South Africa, 7700
GSK Investigational Site
Paarl, South Africa, 7646
GSK Investigational Site
Panorama, South Africa, 7500
GSK Investigational Site
Tygerberg, South Africa, 7505
Spain
GSK Investigational Site
Marbella - Málaga, Andalucia, Spain, 29603
GSK Investigational Site
Laredo, Cantabria, Spain, 39770
GSK Investigational Site
Torrelavega, Cantabria, Spain, 39300
GSK Investigational Site
Badalona, Catalonia, Spain, 08916
GSK Investigational Site
(Badalona) Barcelona, Spain, 08911
GSK Investigational Site
(Barakaldo) Vizcaya, Spain, 48903
GSK Investigational Site
Alicante, Spain, 03004
GSK Investigational Site
Alzira/Valencia, Spain, 46600
GSK Investigational Site
Barcelona, Spain, 08003
GSK Investigational Site
Barcelona, Spain, 08006
GSK Investigational Site
Barcelona, Spain, 08017
GSK Investigational Site
Barcelona, Spain, 08023
GSK Investigational Site
Barcelona, Spain, 08028
GSK Investigational Site
Barcelona, Spain, 08035
GSK Investigational Site
Barcelona, Spain, 08036
GSK Investigational Site
Barcelona, Spain, 08041
GSK Investigational Site
Basurto/Bilbao, Spain, 48013
GSK Investigational Site
Burgos, Spain, 09006
GSK Investigational Site
Centelles (Barcelona), Spain, 08540
GSK Investigational Site
Coslada, Spain, 28822
GSK Investigational Site
Cáceres, Spain, 10003
GSK Investigational Site
Gerona, Spain, 17005
GSK Investigational Site
Girona, Spain, 17007
GSK Investigational Site
L'Hospitalet de Llobregat, Spain, 08907
GSK Investigational Site
La Coruña, Spain, 15006
GSK Investigational Site
La Coruña, Spain, 15011
GSK Investigational Site
La Roca del Valles (Barcelona), Spain, 08430
GSK Investigational Site
Lleida, Spain, 25198
GSK Investigational Site
Madrid, Spain, 28006
GSK Investigational Site
Madrid, Spain, 28040
GSK Investigational Site
Mataró, Spain, 08303
GSK Investigational Site
Málaga, Spain, 29010
GSK Investigational Site
Mérida (Badajoz), Spain, 06800
GSK Investigational Site
Oviedo, Spain, 33006
GSK Investigational Site
Palma de Mallorca, Spain, 07120
GSK Investigational Site
Pamplona, Spain, 31008
GSK Investigational Site
peralada( Girona), Spain, 17491
GSK Investigational Site
Petrer/Alicante, Spain, 03610
GSK Investigational Site
Ponferrada (León), Spain, 24411
GSK Investigational Site
Pozuelo de Alarcón/Madrid, Spain, 28223
GSK Investigational Site
Sabadell (Barcelona), Spain, 08208
GSK Investigational Site
Sagunto/Valencia, Spain, 46520
GSK Investigational Site
Salamanca, Spain, 37007
GSK Investigational Site
San Juan De Alicante, Spain, 3550
GSK Investigational Site
San Sebastian de los Reyes, Spain, 28702
GSK Investigational Site
Santander, Spain, 39008
GSK Investigational Site
Santiago de Compostela, Spain, 15706
GSK Investigational Site
Sevilla, Spain, 41013
GSK Investigational Site
Tarragona, Spain, 43002
GSK Investigational Site
Valencia, Spain, 46015
GSK Investigational Site
Valencia, Spain, 46017
GSK Investigational Site
Valladolid, Spain, 47012
GSK Investigational Site
Vizcaya, Spain, 48902
GSK Investigational Site
Zaragoza, Spain, 50009
Sweden
GSK Investigational Site
Borås, Sweden, SE-506 30
GSK Investigational Site
Göteborg, Sweden, SE-413 45
GSK Investigational Site
Göteborg, Sweden, SE-413 90
GSK Investigational Site
Höllviken, Sweden, SE-236 32
GSK Investigational Site
Linköping, Sweden, SE-587 58
GSK Investigational Site
Luleå, Sweden, SE-971 89
GSK Investigational Site
Stockholm, Sweden, SE-111 57
GSK Investigational Site
Uppsala, Sweden, SE-752 37
GSK Investigational Site
Örebro, Sweden, SE-703 62
GSK Investigational Site
Östersund, Sweden, SE-831 83
Thailand
GSK Investigational Site
Bangkok, Thailand, 10330
GSK Investigational Site
Bangkok, Thailand, 10600
GSK Investigational Site
Chiangmai, Thailand, 50200
GSK Investigational Site
Khon Kaen, Thailand, 40002
GSK Investigational Site
Muang, Thailand, 11000
GSK Investigational Site
Nakhon Ratchasima, Thailand, 30000
GSK Investigational Site
Nan, Thailand, 55000
GSK Investigational Site
Songkla, Thailand, 90110
Turkey
GSK Investigational Site
Ankara, Turkey, 06100
GSK Investigational Site
Istanbul, Turkey, 34020
GSK Investigational Site
Istanbul, Turkey, 34844
GSK Investigational Site
Izmir, Turkey, 35100
GSK Investigational Site
Mersin, Turkey, 33343
Ukraine
GSK Investigational Site
Kharkiv, Ukraine, 61002
GSK Investigational Site
Kharkiv, Ukraine, 61124
GSK Investigational Site
Kiev, Ukraine, 03680
GSK Investigational Site
Kyiv, Ukraine, 02232
GSK Investigational Site
Kyiv, Ukraine, 03049
GSK Investigational Site
Kyiv, Ukraine, 03680
GSK Investigational Site
Mykolayiv, Ukraine, 54003
GSK Investigational Site
Odesa, Ukraine, 65025
GSK Investigational Site
Sumy, Ukraine, 40022
GSK Investigational Site
Vinnytsia, Ukraine, 21000
United Kingdom
GSK Investigational Site
Exeter, Devon, United Kingdom, EX2 5DW
GSK Investigational Site
Romford, Essex, United Kingdom, RM1 3LT
GSK Investigational Site
Wishaw, Lanarkshire, United Kingdom, ML2 0DP
GSK Investigational Site
Blackpool, Lancashire, United Kingdom, FY3 7EN
GSK Investigational Site
Northwood, Middlesex, United Kingdom, HA6 2RN
GSK Investigational Site
High Heaton, Newcastle upon Tyne, Tyne & Wear, United Kingdom, NE7 7DN
GSK Investigational Site
Bradford on Avon, Wiltshire, United Kingdom, BA15 1DQ
GSK Investigational Site
Baillieston, Glasgow, United Kingdom, G69 7AD
GSK Investigational Site
Bradford, United Kingdom, BD9 6RJ
GSK Investigational Site
Cambridge, United Kingdom, CB2 0QQ
GSK Investigational Site
Chester, United Kingdom, CH2 1UL
GSK Investigational Site
Crawley, United Kingdom, RH10 7DX
GSK Investigational Site
Crownhill, Plymouth, United Kingdom, PL5 3JB
GSK Investigational Site
Dundee, Scotland, United Kingdom, DD1 9SY
GSK Investigational Site
Sidcup, Kent, United Kingdom, DA14 6LT
GSK Investigational Site
Stockton-on-Tees, United Kingdom, TS19 8PE
GSK Investigational Site
Trowbridge, United Kingdom, BA14 9AR
Vietnam
GSK Investigational Site
Ha Noi, Vietnam, 10000
GSK Investigational Site
Ho Chi Minh, Vietnam, 70000
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT02164513     History of Changes
Other Study ID Numbers: 116855 
Study First Received: June 12, 2014
Last Updated: September 22, 2016
Health Authority: United States: Food and Drug Administration
Europe: European Medicines Agency

Keywords provided by GlaxoSmithKline:
COPD
umeclidinium
fluticasone furoate
vilanterol
triple therapy
exacerbation

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Chronic Disease
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes
Fluticasone
Bromides
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents
Anticonvulsants

ClinicalTrials.gov processed this record on September 27, 2016